Inside BillionToOne: CEO Atay Oguzhan’s Rule 10b5‑1 Buy‑Sell Trades Revealed

Insider Transactions at BillionToOne: Analysis of Mr. Atay Oguzhan’s Recent Activities

The most recent Form 4 filed on 28 October 2026 by Chairman and CEO Atay Oguzhan details a complex set of trades executed under a Rule 10b5‑1 plan. The transaction involved a simultaneous purchase of 8 333 Class A shares at $2.80 per share, a sale of the same number of shares at $118.00, and a sale of 2 667 shares at the higher price. In addition, an exercise of 8 333 stock‑option contracts at the exercise price of $2.80 was recorded. All trades were completed through Fidelity on the NASDAQ exchange.

1. Transaction Structure and Implications for Ownership

• Net Position: Because the number of shares bought and sold is identical, the net effect on Mr. Oguzhan’s ownership stake is zero. The simultaneous buy‑sell pairs within a pre‑established 10b5‑1 plan suggest a disciplined approach to portfolio management rather than opportunistic trading.
• Liquidity Generation: The sales at higher market prices provide liquidity that may serve personal financial planning or portfolio rebalancing objectives.
• Regulatory Compliance: Execution under a Rule 10b5‑1 plan mitigates concerns about insider influence and aligns with best‑practice governance standards.

2. Historical Trading Patterns

A review of Mr. Oguzhan’s filings from mid‑September through mid‑October 2026 reveals a pattern of large block sales executed during periods of market volatility. The sales ranged from 1 500 to 25 000 shares per transaction, with transaction prices between $95 and $118. Option exercises were similarly frequent, converting at the low exercise price of $2.80 and subsequently selling at higher market levels. This behavior indicates a focus on capital gains and liquidity rather than speculative positioning.

3. Market Context and Company Valuation

• Market Capitalization: Approximately $5.4 billion.
• Price‑to‑Earnings Ratio: 137.73, suggesting high growth expectations but also a potential valuation premium.
• Performance Volatility: A 7.23 % weekly gain juxtaposed with a modest 4.02 % annual rise points to a volatile competitive environment within the health‑tech sector.

Sustained insider selling, even when routine, can erode shareholder confidence if perceived as a divestiture at the expense of employee or retail investors. However, the current pattern—consistent sales at or slightly above market prices—may be interpreted as confidence in the company’s trajectory.

4. Forward‑Looking Considerations

Investors should monitor future disclosures for:

• Shifts in Volume: A sudden increase in trade volume could signal a strategic pivot or reassessment of valuation.
• Price Spread Changes: A widening gap between purchase and sale prices may indicate a change in the insider’s outlook.
• Option Activity: Continued option exercises at low prices followed by sales at high market levels could reaffirm a long‑term investment stance.

Overall, Mr. Oguzhan’s latest Form 4 demonstrates a textbook example of disciplined insider activity: a buy‑sell pair under a Rule 10b5‑1 plan that maintains a net zero effect on ownership while providing liquidity. The broader pattern of trades suggests sustained confidence in BillionToOne’s prospects, tempered by personal financial planning needs.